AI Analysis | Feedback

Here are a few analogies for Soleno Therapeutics:

• A Vertex Pharmaceuticals-in-the-making, but focused on a single rare disease treatment currently in Phase III trials.
• Like Moderna or BioNTech in their clinical development phases, but concentrated on a single drug for a rare genetic disorder.

AI Analysis | Feedback

• Diazoxide Choline Controlled-Release: A once-daily oral tablet currently in Phase III clinical development for the treatment of Prader-Willi Syndrome.

AI Analysis | Feedback

Soleno Therapeutics (SLNO) is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for rare diseases. Its lead product candidate is currently in Phase III clinical development and has not yet been commercialized.

Due to its clinical-stage nature, Soleno Therapeutics does not currently have major customers who purchase commercial products.

AI Analysis | Feedback

Almac Pharma Services Ltd.

Cambrex Corporation

Eurofins Scientific (EUFI.PA)

AI Analysis | Feedback

AI Analysis | Feedback

The key risks to Soleno Therapeutics, Inc. (SLNO) primarily revolve around the challenges and controversies surrounding its lead and only commercial product, VYKAT XR (Diazoxide Choline Controlled-Release or DCCR), for Prader-Willi Syndrome:

1. Safety and Commercial Viability Challenges for VYKAT XR (DCCR) Post-Approval and Related Litigation: Soleno Therapeutics faces significant risks related to the safety and subsequent commercial acceptance of its once-daily oral tablet, VYKAT XR, which has been recently approved for Prader-Willi Syndrome. An activist short seller report in August 2025 alleged serious safety concerns, including a "rapid pile-up of reports of children hospitalized for potential heart failure" shortly after starting the drug, suggesting VYKAT XR could be at risk of market withdrawal. This was followed by the disclosure in September 2025 of a patient death involving VYKAT XR, although the company and treating physician deemed it unrelated to the treatment. These events have reportedly caused a disruption in the drug's launch trajectory, leading to a lower number of new prescriptions and increased discontinuations. Furthermore, Soleno is currently subject to class-action lawsuits alleging that its Phase 3 clinical trial program for DCCR systematically downplayed or concealed significant safety concerns, including issues related to excess fluid retention, which consequently posed greater safety risks and materially lowered the drug's commercial viability and prospects for patient adoption.
2. High Dependency on a Single Product Candidate (VYKAT XR/DCCR) and Past Clinical Trial Endpoint Failure: Soleno Therapeutics' business is substantially dependent on the success of VYKAT XR, as it is their sole therapeutic product candidate. This dependency is amplified by the fact that the DCCR drug, in its initial Phase 3 trial (DESTINY PWS/C601), failed to meet its primary endpoint of change from baseline in hyperphagia. While the company noted improvements in a subgroup of patients and secondary goals, the primary endpoint miss, coupled with the subsequent post-marketing safety concerns and commercial struggles, highlights the critical reliance on a single product whose efficacy and safety profile have faced significant scrutiny.
3. Ongoing Financial Losses and the Need for Additional Funding: As a clinical-stage company with no commercialization history, Soleno Therapeutics has consistently incurred significant losses, which are anticipated to continue. Despite maintaining a strong cash position as of December 31, 2024, the company expects ongoing losses and may require additional funds to support its operations, further product development, and market penetration efforts. The ability to secure such funding on acceptable terms is a significant financial risk, especially given the current challenges and litigation surrounding its lead product.

AI Analysis | Feedback

The most significant emerging threat to Soleno Therapeutics is the potential market entry of competitive therapies for Prader-Willi Syndrome (PWS) that are also in late-stage clinical development or already approved for related conditions. Specifically, **Rhythm Pharmaceuticals (RYTM) with its drug Setmelanotide** is a clear emerging threat. Setmelanotide is an MC4R agonist, already approved for other rare genetic obesity disorders, and is currently in a Phase 3 clinical trial for the treatment of PWS. Should Setmelanotide demonstrate strong efficacy and safety data in its ongoing Phase 3 trial and subsequently gain regulatory approval for PWS, it could directly compete with Soleno's lead candidate, Diazoxide Choline Controlled-Release (DCCR). Given Rhythm's existing commercial infrastructure and experience in rare genetic obesity disorders, a successful launch of Setmelanotide for PWS could significantly impact DCCR's potential market share and commercial success.

AI Analysis | Feedback

Soleno Therapeutics' main product, Diazoxide Choline Controlled-Release (DCCR), also known as Vykat, targets Prader-Willi Syndrome (PWS). The overall market for Prader-Willi Syndrome treatments is substantial and projected to grow.

The total Prader-Willi Syndrome therapeutics market size in the United States was estimated to be approximately USD 500 million in 2023, with expectations for growth during the 2024–2034 forecast period. Across the 7 Major Markets (7MM), which include the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan, the Prader-Willi Syndrome treatment market was valued at over USD 600 million in 2023. This market is anticipated to reach USD 1,302.9 million by 2035, growing at a compound annual growth rate (CAGR) of 6.68% from 2025 to 2035.

For Vykat specifically, Soleno Therapeutics estimates its total addressable market to be approximately 10,000 patients. Based on a drug list price of around $466,000 per year, this implies a market opportunity of approximately $4.7 billion. Analysts have predicted peak revenues for Vykat could range from $1.5 billion to $2 billion, with one analyst forecasting up to $2.5 billion in worldwide yearly sales at its peak.

AI Analysis | Feedback

Soleno Therapeutics (SLNO) is expected to experience future revenue growth over the next 2-3 years driven primarily by the following factors:

1. Continued U.S. Commercialization and Market Penetration of VYKAT XR for Prader-Willi Syndrome: Soleno Therapeutics' lead candidate, VYKAT XR (diazoxide choline controlled-release), received U.S. Food and Drug Administration (FDA) approval on March 26, 2025, for the treatment of hyperphagia in patients with Prader-Willi Syndrome (PWS) aged four years and older, with commercial availability beginning in April 2025. The company has demonstrated strong initial market uptake, reporting full-year 2025 net revenue of $190.4 million, despite less than nine months of commercial sales, and fourth-quarter 2025 net revenue of $91.7 million, marking a nearly 40% sequential increase. As of December 31, 2025, VYKAT XR had received 1,250 patient start forms, representing approximately 12.5% of the estimated U.S. addressable market, with 859 active patients on therapy and coverage for over 185 million lives. Soleno aims to secure approximately 1,000 additional patient start forms over the next 9-12 months. Analysts project that VYKAT XR could generate up to $2.3 billion in peak annual sales in the U.S.
2. European Regulatory Approval and Commercialization of DCC-CR for Prader-Willi Syndrome: Soleno Therapeutics submitted a Marketing Authorization Application (MAA) for diazoxide choline prolonged-release tablets (DCCR) for PWS to the European Medicines Agency (EMA), which was validated in May 2025. The company anticipates an EMA decision around mid-2026. If approved, this would open up a significant new market, as Soleno estimates there are approximately 9,500 PWS patients in key European countries (United Kingdom, France, Germany, Italy, and Spain). Orphan Drug Designation has been granted for diazoxide choline in the EU, potentially offering up to 10 years of market exclusivity upon approval.
3. Expansion of DCC-CR into Additional Rare Disease Indications: Soleno Therapeutics has stated its intention to evaluate diazoxide choline extended-release (DCCR) in other high-need rare diseases to expand its development pipeline. This strategic initiative aims to diversify the company's product offerings and leverage its core technology beyond PWS, potentially unlocking new revenue streams in the future.

AI Analysis | Feedback

Share Repurchases

• In November 2025, Soleno Therapeutics authorized a $100 million share repurchase program through an Accelerated Share Repurchase (ASR) Agreement.
• An initial payment of $100 million was made under the ASR, resulting in an initial delivery of approximately 1,511,553 shares based on the closing price on November 10, 2025.
• The Accelerated Share Repurchase is expected to be completed in the first quarter of 2026.

Share Issuance

• In July 2025, Soleno Therapeutics priced a public offering of 2,352,941 shares of common stock at $85.00 per share, aiming to raise approximately $200 million in gross proceeds to fund the commercialization of VYKAT™ XR, regulatory activities in the EU, and further R&D efforts.
• In May 2024, the company offered 3,000,000 shares of its common stock at $46.00 per share, with expected proceeds before expenses of $129.72 million.
• In October 2023, Soleno Therapeutics closed an underwritten public offering of 3,450,000 shares of common stock at $20.00 per share, generating gross proceeds of $69.0 million.

Inbound Investments

• In October 2023, Soleno Therapeutics closed a concurrent private offering of approximately $60.0 million of shares of common stock and pre-funded warrants, with participation from existing investors including Adage Capital Partners LP, Commodore Capital, Frazier Life Sciences, Nantahala Capital, Perceptive Advisors, and Woodline Partners LP.

Capital Expenditures

• Soleno Therapeutics reported capital expenditures of $0.06 million for the full year 2025 and $0.01 million for the full year 2024.
• For the full year 2023, capital expenditures were $0.58 million.